162 related articles for article (PubMed ID: 31842875)
21. Retrospective comparison between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma.
Gan H; Zhang F; Lin Y
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):397-9. PubMed ID: 12408775
[TBL] [Abstract][Full Text] [Related]
22. Response-based modification of CHOP chemotherapy for canine B-cell lymphoma.
Benjamin SE; Sorenmo KU; Krick EL; Salah P; Walsh KA; Weinstein NM; Keuler NS; Avery AC; Atherton MJ; Lenz JA
Vet Comp Oncol; 2021 Sep; 19(3):541-550. PubMed ID: 33729654
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
24. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.
Hosoya K; Kisseberth WC; Lord LK; Alvarez FJ; Lara-Garcia A; Kosarek CE; London CA; Couto CG
J Vet Intern Med; 2007; 21(6):1355-63. PubMed ID: 18196747
[TBL] [Abstract][Full Text] [Related]
25. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
Yuan ZY; Xu RH; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
[TBL] [Abstract][Full Text] [Related]
26. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases.
Sorenmo K; Overley B; Krick E; Ferrara T; LaBlanc A; Shofer F
Vet Comp Oncol; 2010 Sep; 8(3):196-208. PubMed ID: 20691027
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of neutrophilia as a prognostic factor in dogs with multicentric lymphoma treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy protocol.
Veluvolu S; Pellin M; Vos N
J Am Vet Med Assoc; 2021 Sep; 259(5):494-502. PubMed ID: 34388019
[TBL] [Abstract][Full Text] [Related]
28. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
31. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol.
Tomiyasu H; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2010 Nov; 72(11):1391-7. PubMed ID: 20543531
[TBL] [Abstract][Full Text] [Related]
33. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
[TBL] [Abstract][Full Text] [Related]
34. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of survivin expression in untreated and relapsed canine lymphoma.
Rebhun RB; Lana SE; Ehrhart EJ; Charles JB; Thamm DH
J Vet Intern Med; 2008; 22(4):989-95. PubMed ID: 18647159
[TBL] [Abstract][Full Text] [Related]
36. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
[TBL] [Abstract][Full Text] [Related]
37. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
[TBL] [Abstract][Full Text] [Related]
38. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
39. Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.
Gómez HL; Samanéz C; Campana F; Neciosup SP; Vera L; Casanova L; Leon J; Flores C; de Mendoza FH; Casteñeda CA; Pinto JA; Vallejos CS
Hematol Oncol Stem Cell Ther; 2012; 5(3):152-7. PubMed ID: 23095791
[TBL] [Abstract][Full Text] [Related]
40. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
